“OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY): L. Francesco Iannone1, M. Romozzi2|3, A. Russo4, I. Finkelstein5, D. Seabi6, A. Ahlden6, A. Hege Aamodt7|8|9, P. Calabresi2|3, C. Vollono3, E. Caronna10|11, P. Pozo-Rosich10|11, E. Andreas Tronvik8|12|13, C. Sundal6|12 | 1Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Italy; 2Dipartimento Universitario Di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 3Neurologia, Dipartimento Di Neuroscienze, Organi Di Senso E Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 4Inter-Departmental Program of Headache Medicine and Primary Pain Syndromes, Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania ‘Luigi Vanvitelli’, Naples, Italy; 5Toronto Headache and Pain Clinic; Pain Clinic, Toronto, Canada; 6NeuroClinicNorway, Lillestrøm, Norway; 7Department of Neurology, Oslo University Hospital, Rikshospitalet, Norway; 8NorHead, Norwegian Headache Research Centre; NTNU, Norwegian University of Science and Technology, Trondheim, Norway; 9Institute of Population Health, Faculty of Health and Life Sciences, University of Liverpool, UK; 10Headache and Neurological Pain Research Group, Vall D’Hebron Research Institute, Department of Neuroscience, Universitat Autònoma de Barcelona, Spain; 11Headache Clinic, Neurology Department, Vall D’Hebron Hospital, Barcelona, Spain; 12Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway; 13Neuroclinic, St. Olavs Hospital, Trondheim, Norway”. 2026. Confinia Cephalalgica 36 (s1). https://doi.org/10.4081/cc.2026.15945.